Slowing Disability in MS

About this episode

Daniel Vitt discusses Immunic Therapeutics' experimental therapy aimed at slowing neurodegeneration in multiple sclerosis.

Most existing therapies for multiple sclerosis do a good job of reducing relapses and inflammatory activity, but they largely fail to stop the slow neurodegeneration that drives long-term disability, especially in progressive forms of the disease. Immunic Therapeutics is trying to reshape the treatment landscape for multiple sclerosis with its experimental once-daily oral therapy, designed not only to curb inflammation and relapses but also to tackle the neurodegeneration that silently drives disability progression in both relapsing and progressive forms of MS. Daniel Vitt, CEO of Immunic, discusses how the company’s experimental MS therapy works, how it may protect neurons from cell death, and the potential for its dual mechanism of action to change the treatment landscape.

People in this episode

Guest: Daniel Vitt

Topics covered

• multiple sclerosis
• neurodegeneration
• treatment landscape
• oral therapy
• inflammation
• disability progression

Keywords

• multiple sclerosis
• Immunic Therapeutics
• neurodegeneration
• oral therapy
• disability
• inflammation
• relapses

Mentioned in this episode

Organizations: Immunic Therapeutics, Levine Media Group

Books & works: Slowing Disability in MS

More episodes of The Bio Report

• Stopping Shape-Shifting Tumors with a First-in-Class Epigenetic Drug · June 10, 2026 · 28 min
• Rewriting the Rules of Antibody Drug Design · June 3, 2026 · 38 min
• Mapping Cellular Stress Biology to Tackle Undruggable Targets · May 27, 2026 · 30 min
• Turning Abandoned Drugs into Breakthroughs · May 20, 2026 · 31 min
• Targeting Cancer Survival Genes in Solid Tumors · May 13, 2026 · 46 min
• Addressing Treatment Gaps in Gout · May 6, 2026 · 37 min